KOSDAQ-listed Samchundang Pharmaceutical (000250.KQ) plunged more than 10% in after-hours trading on May 6.
As of 7:40 p.m. that day, shares of the company were trading at 556,000 won, down 10.03% from its regular session closing price of 618,000 won.
Samchundang Pharmaceutical earlier that day moved to publicly address the controversy surrounding its technology and contract structure by releasing documents submitted to the U.S. Food and Drug Administration (FDA) and patent review materials.
Original reporting by Kim Kyung-taek for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
Watch · Seoul Economic Daily
More →A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Pre-register for SIGNAL English Edition — a premium subscription bringing Korean capital markets coverage (M&A, IPOs, private equity, fund flows) to global institutional investors. First access to the 50% introductory rate.
